Poor bioavailability by the oral route is noticeable with the majority of new active pharmaceutical ingredients due to its dissolution rate limited absorption. A second-generation thienopyridine antiplatelet drug, though, it is BCS class II drug results in poor oral bioavailability. The present investigation was undertaken to prepare polymeric nanosponges to achieve improved solubility of clopidogrel bisulphate. Nanosponges using ethyl cellulose as a polymer and glutarldehyde as a cross-linker were prepared successfully by emulsion solvent diffusion method. Drug polymer compatibility study were performed by FTIR and DSC. To obtain optimized batch, 32 factorial designs were performed and all batches were evaluated. C1-C9 batches yields particle size (nm) between 87.28-183(nm), % drug content between 71.073±1.066 -88.663 ±0.549, % entrapment efficiency between 51.719±0.775- 81.765±0.506, % drug release 75.120±0.407-97.416±0.336. Optimized batch exhibited particle size 87.28nm, % drug content 88.663 ±0.549, % entrapment efficiency 81.765±0.506, % drug release 97.416±0.336. An SEM and TEM image of optimized batch shows spongy and spherical nature of nanosponges. The optimized nanosponge formulations were converted into tablets to achieve immediate release drug delivery for oral route. These tablets were prepared using crospovidone and pregelatinised starch. All nine tablet batches were evaluated and F3 batch shows good results i.e. hardness (kg/cm2) 3.71±0.04, in- vitro disintegration time (min) 3.21±0.025 and % drug release 99.18±1.38. In vitro dissolution studies indicate that percent cumulative drug release follows zero order kinetics. Accelerated and long term stability data revealed no significant change in drug content and drug release at the end of 6 months. In conclusion, nanosponges could be a newly emerging approach to enhance aqueous solubility of BCS Class II drugs.
Cite this article:
Shweta S. Gedam, Ganesh D. Basarkar. Formulation, Design and In-Vitro Characterization of Clopidogrel Bisulphate Nanosponge Tablets for Oral Administration. Research Journal of Pharmacy and Technology. 2021; 14(4):2069-5. doi: 10.52711/0974-360X.2021.00367
Shweta S. Gedam, Ganesh D. Basarkar. Formulation, Design and In-Vitro Characterization of Clopidogrel Bisulphate Nanosponge Tablets for Oral Administration. Research Journal of Pharmacy and Technology. 2021; 14(4):2069-5. doi: 10.52711/0974-360X.2021.00367 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-4-43
1. Altman R. Risk factors in coronary atherosclerosis atheroinflammation: the meeting point, Thromb J. 2003; 1: 4-4.
2. Bray PF. Platelet hyper-reactivity: predictive and intrinsic properties, Hematol/Oncol Clin North Am. 2007; 21: 633-6.
3. Kumar K P, Subash V, Reddy NY. Clopidogrel - an overview, International Journal of Pharmacology Research. 2013;3(1): 1-7.
4. Dahanand A, Haffman A. Rationalizing the selection of oral liquid based drug delivery systems by an in-vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs, Journal of Controlled Release. 008; 129(1): 1-10
5. Chakraborty S, Shukla D, Singh S. Lipid an emerging platform for oral delivery of drugs with poor bioavailability, European Journal of Pharmaceutics and Biopharmaceutics. 2009; 73(1): 1-15.
6. Subramanian S, Singireddy A, Krishnamoorthy K, Rajappan M. Nanosponges: a novel class of drug delivery system –Review, Journal of Pharm Pharmaceutical Sci. 2012; 5(1): 103-11.
7. Jenny A, Merima P, Alberto F, Francesco T. Role of β- cyclodextrin nanosponges in polypropylene Photooxidation, Carbohydrate Polymers. 2011; 86: 127-35.
8. IP 2010, Volume II, Government of India, Ministry of Health and Family welfare, published by the Indian Pharmacopoeia Commission, Ghaziabad, 1119-20.
9. Koradia V, Chawla G, Bansal A. Qualitative and quantitative analysis of clopidogrel bisulphate polymorphs, Acta Pharm. 2004; 54: 193–204.
10. Lira LM, Lourenco AL, Neves GF, Sousa VPD, Rodrigues CR, Cabral LM. Assessment of analytical techniques for characterization of crystalline clopidogrel forms in patent applications, Brazilian Journal of Pharmaceutical Sciences. 2014; 50(2): 229-242.
11. Bolmal UB, Manvi FV, Rajkumar K. Recent Advances in Nanosponges as Drug Delivery System, International Journal of Pharmaceutical Sciences and Nanotechnology. 2013;6(1):1934-1944.
12. Gedam SS, Jadhav P, Talele SG, Jadhav A. Effect of crosslinking agent on development of gastroretentive mucoadhesive microspheres of risedronate sodium, International Journal of Applied Pharmaceutics. 2018; 10(4): 134-140.
13. Antonio Z, Antunes T, Saini G, Macgregor A. Factorial design used in optimization immediate release solid dosage ranitidine HCl, Estud. biol. 2006; 28: 17-25.
14. Gedam SS, Basarkar GD. Nanosponges: An Attractive Strategy for Enhanced Therapeutic Profile, J. Pharm. Sci. and Res. 2019; 11(6): 2479-2487.
15. Indian Pharmacopoeia 2010 Volume II, Govt. of India, Ministry of Health and Family welfare, published by the Indian Pharmacopoeia Commission, Ghaziabad. 1417-18.
16. Hiremath SN, Raghavendra RK, Danki LS. Dissolution enhancement of gliclazide by preparation of inclusion complexes with β-cyclodextrin, Asian Journal of Pharmaceutics. 2014; 1: 73-76.
17. Atram SC. Formulation and evaluation of immediate release tablet using response surface methodology, Asian Journal of Pharmaceutics. 2011; 1(1): 46-51.
18. Pande V, Karale P, Goje P, Mahanavar S. An overview on emerging trends in immediate release tablet technologies, Austin Therapeutics. 2016; 3(1): 1-8.
19. Lakka NS, Goswami N. Solubility and dissolution profile studies of gliclazide in pharmaceutical formulations by RP-HPLC, Int. Res. J. Ph. 2012; 3(6): 126-129.
20. Jadhav SB, Mali Rajeghadage SH and Bathe RS. Formulation and evaluation of immediate release tablets of imipramine hydrochloride, International Journal of Biomedical and Advance Research. 2014; 5(11): 559- 565.
21. Vamshi PV, Rao GC, Reddy DS, Reddy VP. The effect of different superdisintegrants and their concentrations on the dissolution of topiramate immediate release tablets. International Journal of Pharmaceutical Sciences and Nanotechnology 2009; 2(2): 531-536.